MedTrace Logo

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

NCT05821192 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-04-20

No results posted yet for this study

Summary

A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously shown promising efficacy.

Conditions

  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma

Interventions

DRUG

Rituximab

375mg/m2 by IV infusion once every 3 weeks

DRUG

Gemcitabine

1 g/m2 on Days 1 by IV infusion once every 3 weeks

DRUG

Dexamethasone

40 mg on Days 1 to 4 of each 3-week cycle by IV infusion

DRUG

Cisplatin

75 mg/m2 on Days 1 by IV infusion once every 3 weeks

DRUG

PD-1 monoclonal antibody

200mg on Days 2 by IV infusion once every 3 weeks

Sponsors & Collaborators

  • Second Hospital of Jilin University

    collaborator OTHER

  • China-Japan Union Hospital, Jilin University

    collaborator OTHER

  • Ou Bai, MD/PHD

    lead OTHER

Principal Investigators

  • Ou Bai, doctor · The First Hospital of Jilin University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-23
Primary Completion
2023-04-18
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821192 on ClinicalTrials.gov